RedHill's Turnaround: Strategic Deals Fuel Financial Rebound

TEL AVIV, Israel and RALEIGH, N.C. – April 27, 2026 – In a challenging year for the biopharmaceutical industry, RedHill Biopharma Ltd. has engineered a significant financial and strategic turnaround, reporting a year-end shift from a capital deficiency to positive equity. The company’s full-year 2025 results, announced today, highlight a series of transformative deals, key advancements in its research pipeline, and a legal victory that collectively place the firm on more solid ground.

RedHill ended 2025 with positive equity of $4.3 million, a stark reversal from the $4.7 million capital deficiency recorded at the end of 2024. The company's CEO, Dror Ben-Asher, described 2025 as a year that demonstrated "business tenacity, the strategic transactions that we successfully accomplished and the traction we have achieved in progressing key commercial, R&D and financial objectives."

Reshaping the Commercial Landscape

A cornerstone of RedHill's 2025 strategy was the transformation of its flagship commercial product, Talicia, an FDA-approved therapy for Helicobacter pylori infection. In October, RedHill formed a U.S. co-commercialization partnership with Cumberland Pharmaceuticals. The deal established Talicia Holdings Inc. (THI), a new entity in which RedHill maintains a 70% stake. Cumberland invested $4 million for its 30% share and committed its national sales force to bolster Talicia's market penetration under an agreement that sees the two companies equally share the product's net revenues in the United States.

The partnership landscape evolved further when Cumberland and Canadian-based Apotex announced a planned strategic transaction in early 2026 to integrate Cumberland's U.S. branded business. While the full operational impact on the Talicia partnership remains to be seen, the underlying structure of THI provides RedHill with a defined revenue stream. This strategic pivot moves RedHill away from the high costs of direct commercialization while retaining significant economic interest.

Talicia's commercial prospects were also boosted by expanded insurance coverage, with Humana adding the drug to its Medicare Part D formulary, covering an additional eight million lives. The company also expanded its licensing activities for Talicia in the Middle East, generating approximately $1.9 million in revenue from these discontinued operations in 2025.

Unlocking Value Through Licensing and Legal Wins

Beyond its Talicia strategy, RedHill executed several other transactions to strengthen its balance sheet. In February 2025, it licensed the ex-North American rights for RHB-102 (Bekinda) to Hyloris Pharmaceuticals. The deal could be worth up to $60 million in potential milestone payments, in addition to tiered royalties on net sales, providing a significant source of non-dilutive funding.

Further bolstering its financial position, RedHill secured a major legal victory against Kukbo Co. Ltd. In November, a New York Supreme Court ruling awarded RedHill over $10.5 million, a judgment that is now final and eligible for enforcement. While the company notes that collection remains subject to future realization, the finality of the ruling marks a decisive win. To improve its liquidity, the company also established a $10 million line of credit with Alumni Capital LP, giving it the right to sell American Depositary Shares (ADSs) as needed.

These corporate maneuvers were instrumental in improving the company's financial health. "We have unlocked significant opportunity for the Company through strategic transactions," Ben-Asher stated, emphasizing the company's improved balance sheet and leaner operational footprint.

A Pipeline Targeting Billion-Dollar Markets

With its commercial business restructured, RedHill has sharpened its focus on a diverse R&D pipeline targeting significant unmet needs in gastroenterology and oncology.

One of the most promising assets is RHB-102 (Bekinda), which is being repositioned to address a major challenge in the booming obesity and diabetes market. This market, projected to reach $100 billion, is dominated by GLP-1/GIP receptor agonists like Ozempic and Mounjaro. However, up to 50% of patients reportedly discontinue these therapies within months, often due to gastrointestinal side effects like nausea and vomiting. RedHill is advancing Bekinda, a once-daily oral anti-emetic, as a potential solution to improve patient adherence, a move that could tap into a substantial market opportunity.

In Crohn's disease, RedHill is advancing RHB-204, a therapy that represents a potential paradigm shift. Unlike existing treatments that manage symptoms, RHB-204 is a combination antibiotic therapy designed to target a suspected root cause of the disease: the Mycobacterium avium subspecies paratuberculosis (MAP) bacterium. Following positive FDA feedback on its approval pathway, RedHill has initiated collaborations to develop rapid MAP diagnostics, a crucial step for its planned Phase 2 study in a specifically defined MAP-positive patient population.

RedHill's oncology candidate, opaganib, is also making strides. A Phase 2 study is underway evaluating opaganib in combination with Bayer's blockbuster drug darolutamide for advanced prostate cancer. The company also reported promising new preclinical data for opaganib as an add-on therapy in neuroblastoma, chronic lymphocytic leukemia (CLL), and triple-negative breast cancer. With an Orphan Drug designation for neuroblastoma, discussions for further development are ongoing with academic and non-profit partners.

A Closer Look at the Financials: Recovery and Risks

The financial statements reflect the complexity of RedHill's transitional year. The company's direct Talicia commercial operations were reclassified as "discontinued operations" following the Cumberland transaction, which significantly impacts year-over-year comparisons. Net income from these discontinued operations was $7.7 million in 2025, a major swing from an $8.6 million loss in 2024, primarily due to the gain recognized from the THI transaction.

However, the company's continuing operations posted an operating loss of $7.9 million for 2025. While the balance sheet shows a healthier equity position and a cash balance of $4.1 million, the company’s own annual report filing includes a note of caution. Management has expressed substantial doubt about its ability to continue as a "going concern," stating that its current cash is not sufficient to fund operations for more than a year. This underscores the critical importance of realizing cash from its legal victory, achieving milestones from its licensing deals, and potentially raising additional capital.

In his summary of the year, Ben-Asher acknowledged the industry's difficulties but concluded on a note of confidence. "We have ended the year better positioned than we started... we are now on stronger footing for further growth."